Publications by authors named "E Ros-Cucurull"
Article Synopsis
- Schizophrenia and substance use disorders (SUDs) often occur together, creating clinical challenges like poor mental health, low medication adherence, and high rates of relapse and hospitalization.
- This narrative review highlights the need for better diagnosis and treatment for patients with these comorbid conditions by examining current evidence and the healthcare system's management practices.
- Effective treatment should include both pharmacological options, such as partial dopamine agonists, and psychosocial support through an integrated approach that fosters collaboration among healthcare providers and patients.
Background: The COVID-19 pandemic has impacted the mental health of patients with substance use disorder (SUD). However, few longitudinal studies have been done which examine associations between the pandemic, SUD patients' mental health and their drug use.
Objectives: This study aimed to examine duration of abstinence according to psychiatric status among SUD outpatients followed-up for 18 months from the pandemic related lockdown.
Alexithymia is highly prevalent in patients with substance use disorders (SUDs) and has been implied in SUD pathogenesis and treatment outcomes. However, the psychometric properties of the most-used instrument for evaluating alexithymia (the 20-item Toronto Alexithymia Scale, TAS-20) have been scarcely studied in relation to SUD patients.
View Article and Find Full Text PDFCannabis and synthetic cannabinoids (SC) are related to several neuropsychiatric symptoms and disorders, especially psychotic symptoms and disorders. Interestingly, catatonia-like symptoms associated with cannabis and SC have been generally neglected in research and scarcely described despite the clinical repercussions. Hence, this review aims to analyze current clinical publications on catatonia induced by cannabis or SC in a systematized way.
View Article and Find Full Text PDF